Startup Spiro Medical snares $67M in series A funding for asthma treatment

The new year has ushered in a flow of biotech-specific funds, including $700 million from Andreessen Horowitz.

Parabiosis Medicines raises $305 million to upend the status quo Biotech startup Parabiosis Medicines has raised $305 million in a Series A financing round led by ARCH Venture Partners, with participation from Perceptive Advisors and…

Ventyx has achieved its goal of securing Big Pharma commitment to its pipeline, with Eli Lilly swooping in to buy the inflammation biotech outright for $1.2 billion.

Alveus Therapeutics, which launched Thursday under the stewardship of former I-Mab CEO Raj Kannan, is hoping its development candidates can overcome pitfalls common to existing obesity medicines.

Foresee Pharmaceuticals has sold a chunk of its clinical-stage pipeline in order to focus on the potential of its prostate cancer med Camcevi.

Protein degradation biotech EpiBiologics has brought in $107 million in a star-studded series B round headed up by Johnson & Johnson's and Google's respective venture arms.

Lexeo Therapeutics is teaming up with Big Pharma’s Johnson & Johnson unit Abiomed to tap its Impella heart pump technology in search of a potentially safer and more effective route for cardiac genetic medicines.

Tessera Therapeutics is planning to lay off 90 employees, the Flagship-founded biotech has warned.